Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline

Authors: Naoki Aomatsu, Masakazu Yashiro, Shinichiro Kashiwagi, Hidemi Kawajiri, Tsutomu Takashima, Masahiko Ohsawa, Kenichi Wakasa, Kosei Hirakawa

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Neoadjuvant chemotherapy (NAC) is one of the standard care regimens for patients with resectable early-stage breast cancer. It would be advantageous to determine the chemosensitivity of tumors before initiating NAC. One of the parameters potentially compromising such chemosensitivity would be a hypoxic microenvironment of cancer cells. The aim of this study was thus to clarify the correlation between expression of the hypoxic marker carbonic anhydrase-9 (CA9) and chemosensitivity to NAC as well as prognosis of breast cancer patients.

Methods

A total of 102 patients with resectable early-stage breast cancer was treated with NAC consisting of FEC (5-fluorouracil, epirubicin, and cyclophosphamide) followed by weekly paclitaxel before surgery. Core needle biopsy (CNB) specimens and resected tumors were obtained from all patients before and after NAC, respectively. Chemosensitivity to NAC and the prognostic potential of CA9 expression were evaluated by immunohistochemistry.

Results

CA9 positivity was detected in the CNB specimens from 47 (46%) of 102 patients. The CA9 expression in CNB specimens was significantly correlated with pathological response, lymph node metastasis, and lymph-vascular invasion. Multivariate analysis revealed that the CA9 expression in CNB specimens was an independent predictive factor for pathological response. The Kaplan-Meier survival curve revealed a significant negative correlation (p = 0.013) between the disease-free survival (DFS) and the CA 9 expression in resected tissues after NAC. Multivariate regression analyses indicated that the CA9 expression in resected tissues was an independent prognostic factor for DFS.

Conclusions

CA9 expression in CNB specimens is a useful marker for predicting chemosensitivity, and CA9 expression in resected tissue is prognostic of DFS in patients with resectable early-stage breast cancer treated by sequential FEC and weekly paclitaxel prior to resection.
Appendix
Available only for authorised users
Literature
1.
Mayer EL, Carey LA, Burstein HJ: Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007, 9 (5): 110-10.1186/bcr1755.CrossRefPubMedPubMedCentral
2.
Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH: Primary systemic therapy of breast cancer. Oncologist. 2006, 11 (6): 574-589. 10.1634/theoncologist.11-6-574.CrossRefPubMed
3.
Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 1997, 15 (7): 2483-2493.PubMed
4.
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr. 2001, 30: 96-102.CrossRefPubMed
5.
Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2003, 21 (22): 4165-4174. 10.1200/JCO.2003.12.005.CrossRefPubMed
6.
Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002, 20 (6): 1456-1466. 10.1200/JCO.20.6.1456.CrossRefPubMed
7.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18 (7): 1133-1144. 10.1093/annonc/mdm271.CrossRefPubMed
8.
Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA: Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol. 2012, 19 (1): 253-258. 10.1245/s10434-011-1877-y.CrossRefPubMed
9.
Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002, 86 (7): 1041-1046. 10.1038/sj.bjc.6600210.CrossRefPubMedPubMedCentral
10.
Jones RL, Smith IE: Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006, 7 (10): 869-874. 10.1016/S1470-2045(06)70906-8.CrossRefPubMed
11.
Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005, 23 (13): 2988-2995. 10.1200/JCO.2005.06.156.CrossRefPubMed
12.
Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2006, 24 (13): 2019-2027. 10.1200/JCO.2005.04.1665.CrossRefPubMed
13.
Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J: Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res. 2003, 9 (2): 686-692.PubMed
14.
Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O: Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon. 2006, 4 (4): 211-219. 10.1016/S1479-666X(06)80062-4.CrossRefPubMed
15.
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN: Breast cancer biomarkers. Adv Clin Chem. 2005, 40: 99-125.CrossRefPubMed
16.
Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzotti G, Goldhirsch A: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004, 10 (19): 6622-6628. 10.1158/1078-0432.CCR-04-0380.CrossRefPubMed
17.
Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007, 16 (1): 86-93. 10.1016/j.breast.2006.06.008.CrossRefPubMed
18.
Liao SY, Brewer C, Zavada J, Pastorek J, Pastorekova S, Manetta A, Berman ML, DiSaia PJ, Stanbridge EJ: Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. The American journal of pathology. 1994, 145 (3): 598-609.PubMedPubMedCentral
19.
Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994, 9 (10): 2877-2888.PubMed
20.
Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R, Pastorek J: Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 1996, 33 (3): 480-487. 10.1006/geno.1996.0223.CrossRefPubMed
21.
Chen CL, Chu JS, Su WC, Huang SC, Lee WY: Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Archiv: an international journal of pathology. 2010, 457 (1): 53-61. 10.1007/s00428-010-0938-0.CrossRef
22.
Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC: Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer biology & therapy. 2007, 6 (1): 70-75.CrossRef
23.
Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC: Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2009, 73 (4): 1177-1186. 10.1016/j.ijrobp.2008.12.004.CrossRefPubMedPubMedCentral
24.
Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. The American journal of pathology. 2001, 158 (3): 905-919. 10.1016/S0002-9440(10)64038-2.CrossRefPubMedPubMedCentral
25.
Neri D, Supuran CT: Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011, 10 (10): 767-777. 10.1038/nrd3554.CrossRefPubMed
26.
Svastova E, Hulikova A, Rafajova M, Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S: Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577 (3): 439-445. 10.1016/j.febslet.2004.10.043.CrossRefPubMed
27.
Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL: New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene. 2010, 29 (50): 6509-6521. 10.1038/onc.2010.455.CrossRefPubMed
28.
Grabmaier K, AdW MC, Verhaegh GW, Schalken JA, Oosterwijk E: Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene. 2004, 23 (33): 5624-5631. 10.1038/sj.onc.1207764.CrossRefPubMed
29.
Betof AS, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, Dewhirst MW, Blackwell KL: Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer. 2012, 106 (5): 916-922. 10.1038/bjc.2012.32.CrossRefPubMedPubMedCentral
30.
Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O'Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, Harris AL, Fox SB: The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer. 2009, 100 (2): 405-411. 10.1038/sj.bjc.6604844.CrossRefPubMedPubMedCentral
31.
Curran S, Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000, 36 (13 Spec No): 1621-1630.CrossRefPubMed
32.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996, 379 (6560): 88-91. 10.1038/379088a0.CrossRefPubMed
33.
Singletary SE, Greene FL: Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol. 2003, 21 (1): 53-59. 10.1002/ssu.10021.CrossRefPubMed
34.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer. 1981, 47 (1): 207-214. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6.CrossRefPubMed
35.
Kurosumi M, Akashi-Tanaka S, Akiyama F, Komoike Y, Mukai H, Nakamura S, Tsuda H: Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 2008, 15 (1): 5-7. 10.1007/s12282-007-0016-x.CrossRefPubMed
36.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y: Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008, 110 (3): 531-539. 10.1007/s10549-007-9744-z.CrossRefPubMed
37.
Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N: Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010, 17 (4): 269-275. 10.1007/s12282-009-0161-5.CrossRefPubMed
38.
Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, Wakasa K, Hirakawa K: CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PloS one. 2012, 7 (9): e45865-10.1371/journal.pone.0045865.CrossRefPubMedPubMedCentral
39.
Shien T, Shimizu C, Seki K, Shibata T, Hojo T, Ando M, Kohno T, Katsumata N, Akashi-Tanaka S, Kinoshita T, Fujiwara Y: Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome. Breast Cancer Res Treat. 2009, 113 (2): 307-313. 10.1007/s10549-008-9935-2.CrossRefPubMed
40.
Pinder SE, Provenzano E, Earl H, Ellis IO: Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007, 50 (4): 409-417. 10.1111/j.1365-2559.2006.02419.x.CrossRefPubMed
41.
Sahoo S, Lester SC: Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Archives of pathology & laboratory medicine. 2009, 133 (4): 633-642.
42.
Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N: Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B-18. Cancer. 2002, 95 (4): 681-695. 10.1002/cncr.10741.CrossRefPubMed
43.
Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986, 46 (5): 2578-2581.PubMed
44.
Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, Kairaluoma MI, Karttunen TJ: Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. The American journal of pathology. 1998, 153 (1): 279-285. 10.1016/S0002-9440(10)65569-1.CrossRefPubMedPubMedCentral
45.
Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK: Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res. 2002, 8 (4): 1284-1291.PubMed
46.
Bartosova M, Parkkila S, Pohlodek K, Karttunen TJ, Galbavy S, Mucha V, Harris AL, Pastorek J, Pastorekova S: Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol. 2002, 197 (3): 314-321. 10.1002/path.1120.CrossRefPubMed
47.
Potter CP, Harris AL: Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer. 2003, 89 (1): 2-7. 10.1038/sj.bjc.6600936.CrossRefPubMedPubMedCentral
48.
Span PN, Bussink J, Manders P, Beex LV, Sweep CG: Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer. 2003, 89 (2): 271-276. 10.1038/sj.bjc.6601122.CrossRefPubMedPubMedCentral
49.
Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001, 19 (16): 3660-3668.PubMed
50.
Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL: Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer. 2006, 13 (3): 921-930. 10.1677/erc.1.01216.CrossRefPubMed
51.
Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, Winum JY, Scozzafava A, Supuran CT, Williams KJ: Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012, 55 (11): 5591-5600. 10.1021/jm300529u.CrossRefPubMed
Metadata
Title
Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
Authors
Naoki Aomatsu
Masakazu Yashiro
Shinichiro Kashiwagi
Hidemi Kawajiri
Tsutomu Takashima
Masahiko Ohsawa
Kenichi Wakasa
Kosei Hirakawa
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-400

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells

Research article

The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype

Research article

Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer

Case report

Primary ectopic atypical meningioma in the renal hilum: a case report

Research article

Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer

Case report

A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits